Constitutive androstane receptor transactivates the hepatic expression of mouse Dhcr24 and human DHCR24 encoding a cholesterogenic enzyme 24-dehydrocholesterol reductase

Toxicology Letters

Volumn 208, Issue 2, 2012, Pages 185-191

  Yoshinari, Kouichi ^a   Ohno, Hitoshi ^a   Benoki, Satoshi ^a   Yamazoe, Yasushi ^a  

^a TOHOKU UNIVERSITY   (Japan)

Author keywords

CAR; Cholesterol biosynthesis; Hepatocyte; Nuclear receptor; Phenobarbital; Transcription

Indexed keywords

24 DEHYDROCHOLESTEROL REDUCTASE; CHOLESTEROL DERIVATIVE; CONSTITUTIVE ANDROSTANE RECEPTOR; MESSENGER RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CATALYSIS; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; GEL MOBILITY SHIFT ASSAY; HEPATOMA CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LIVER CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSACTIVATION;

ANIMALS; ENZYME ACTIVATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; GENES, REPORTER; HEPATOCYTES; HUMANS; LIVER; MALE; MICE; MICE, INBRED C57BL; NERVE TISSUE PROTEINS; OXIDOREDUCTASES ACTING ON CH-CH GROUP DONORS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTIONAL ACTIVATION;

MUS; RODENTIA;

EID: 82255173809     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2011.11.003     Document Type: Article

References (38)

1. Abernethy D.R., Azarnoff D.L. Effect of drugs which alter microsomal drug-metabolizing enzyme activity on rat hepatic cholesterol biosynthesis. Biochem. Pharmacol. 1977, 26:481-484.
2. Andersson H.C., Kratz L., Kelley R. Desmosterolosis presenting with multiple congenital anomalies and profound developmental delay. Am. J. Med. Genet. 2002, 113:315-319.
3. Benvenuti S., Luciani P., Vannelli G.B., Gelmini S., Franceschi E., Serio M., Peri A. Estrogen and selective estrogen receptor modulators exert neuroprotective effects and stimulate the expression of selective Alzheimer's disease indicator-1, a recently discovered antiapoptotic gene, in human neuroblast long-term cell cultures. J. Clin. Endocrinol. Metab. 2005, 90:1775-1782.
4. Blanco-Bose W.E., Murphy M.J., Ehninger A., Offner S., Dubey C., Huang W., Moore D.D., Trumpp A. C-Myc and its target FoxM1 are critical downstream effectors of constitutive androstane receptor (CAR) mediated direct liver hyperplasia. Hepatology 2008, 48:1302-1311.
5. Burk O., Arnold K.A., Geick A., Tegude H., Eichelbaum M. A role for constitutive androstane receptor in the regulation of human intestinal MDR1 expression. Biol. Chem. 2005, 386:503-513.
6. Diwan B.A., Lubet R.A., Ward J.M., Hrabie J.A., Rice J.M. Tumor-promoting and hepatocarcinogenic effects of 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene (TCPOBOP) in DBA/2NCr and C57BL/6NCr mice and an apparent promoting effect on nasal cavity tumors but not on hepatocellular tumors in F344/NCr rats initiated with N-nitrosodiethylamine. Carcinogenesis 1992, 13:1893-1901.
7. Goerdt C., Keith M., Rubins H.B. Effects of phenytoin on plasma high-density lipoprotein cholesterol levels in men with low levels of high-density lipoprotein cholesterol. J. Clin. Pharmacol. 1995, 35:767-775.
8. Goldstein J.L., Brown M.S. Regulation of the mevalonate pathway. Nature 1990, 343:425-430.
9. Goodwin B., Hodgson E., D'Costa D.J., Robertson G.R., Liddle C. Transcriptional regulation of the human CYP3A4 gene by the constitutive androstane receptor. Mol. Pharmacol. 2002, 62:359-365.
10. Goodwin B., Moore L.B., Stoltz C.M., McKee D.D., Kliewer S.A. Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor. Mol. Pharmacol. 2001, 60:427-431.
11. Greeve I., Hermans-Borgmeyer I., Brellinger C., Kasper D., Gomez-Isla T., Behl C., Levkau B., Nitsch R.M. The human DIMINUTO/DWARF1 homolog seladin-1 confers resistance to Alzheimer's disease-associated neurodegeneration and oxidative stress. J. Neurosci. 2000, 20:7345-7352.
12. Heller F.R., Desager J.P., Harvengt C. Changes in plasma activities of lipolytic enzymes and lipids of normolipidemic subjects given phenobarbital, a strong microsomal inducer, alone or in combination with fenofibrate. Int. J. Clin. Pharmacol. Ther. Toxicol. 1988, 26:138-142.
13. Inoue S., Yoshinari K., Sugawara M., Yamazoe Y. Activated sterol regulatory element-binding protein-2 suppresses hepatocyte nuclear factor-4-mediated Cyp3a11 expression in mouse liver. Mol. Pharmacol. 2011, 79:148-156.
14. Kakizaki S., Yamazaki Y., Takizawa D., Negishi M. New insights on the xenobiotic-sensing nuclear receptors in liver diseases-CAR and PXR. Curr. Drug Metab. 2008, 9:614-621.
15. Kiyosawa N., Tanaka K., Hirao J., Ito K., Niino N., Sakuma K., Kanbori M., Yamoto T., Manabe S., Matsunuma N. Molecular mechanism investigation of phenobarbital-induced serum cholesterol elevation in rat livers by microarray analysis. Arch. Toxicol. 2004, 78:435-442.
16. Klaassen C.D., Slitt A.L. Regulation of hepatic transporters by xenobiotic receptors. Curr. Drug Metab. 2005, 6:309-328.
17. Kodama S., Koike C., Negishi M., Yamamoto Y. Nuclear receptors CAR and PXR cross talk with FOXO1 to regulate genes that encode drug-metabolizing and gluconeogenic enzymes. Mol. Cell. Biol. 2004, 24:7931-7940.
18. Konno Y., Negishi M., Kodama S. The roles of nuclear receptors CAR and PXR in hepatic energy metabolism. Drug Metab. Pharmacokinet. 2008, 23:8-13.
19. Korhonen T., Uusitupa M., Voutilainen E., Sarlund H., Laakso M., Laitinen M., Silvasti M., Pyorala K. Lack of effect of hepatic enzyme induction on metabolic control in patients with type 2 (non-insulin-dependent) diabetes. Clin. Pharmacol. Ther. 1987, 41:633-638.
20. Luciani P., Deledda C., Rosati F., Benvenuti S., Cellai I., Dichiara F., Morello M., Vannelli G.B., Danza G., Serio M., Peri A. Seladin-1 is a fundamental mediator of the neuroprotective effects of estrogen in human neuroblast long-term cell cultures. Endocrinology 2008, 149:4256-4266.
21. Luoma P.V., Sotaniemi E.A., Pelkonen R.O., Arranto A., Ehnholm C. Plasma high-density lipoproteins and hepatic microsomal enzyme induction. Relation to histological changes in the liver. Eur. J. Clin. Pharmacol. 1982, 23:275-282.
22. Maglich J.M., Lobe D.C., Moore J.T. The nuclear receptor CAR (NR1I3) regulates serum triglyceride levels under conditions of metabolic stress. J. Lipid Res. 2009, 50:439-445.
23. Miller M., Burgan R.G., Osterlund L., Segrest J.P., Garber D.W. A prospective, randomized trial of phenytoin in nonepileptic subjects with reduced HDL cholesterol. Arterioscler. Thromb. Vasc. Biol. 1995, 15:2151-2156.
24. Miyata M., Nomoto M., Sotodate F., Mizuki T., Hori W., Nagayasu M., Yokokawa S., Ninomiya S., Yamazoe Y. Possible protective role of pregnenolone-16 alpha-carbonitrile in lithocholic acid-induced hepatotoxicity through enhanced hepatic lipogenesis. Eur. J. Pharmacol. 2010, 636:145-154.
25. Pascussi J.M., Gerbal-Chaloin S., Drocourt L., Maurel P., Vilarem M.J. The expression of CYP2B6, CYP2C9 and CYP3A4 genes: a tangle of networks of nuclear and steroid receptors. Biochim. Biophys. Acta 2003, 1619:243-253.
26. Pedretti A., Bocci E., Maggi R., Vistoli G. Homology modelling of human DHCR24 (seladin-1) and analysis of its binding properties through molecular docking and dynamics simulations. Steroids 2008, 73:708-719.
27. Peri A., Danza G., Benvenuti S., Luciani P., Deledda C., Rosati F., Cellai I., Serio M. New insights on the neuroprotective role of sterols and sex steroids: the seladin-1/DHCR24 paradigm. Front. Neuroendocrinol. 2009, 30:119-129.
28. Rezen T., Tamasi V., Lovgren-Sandblom A., Bjorkhem I., Meyer U.A., Rozman D. Effect of CAR activation on selected metabolic pathways in normal and hyperlipidemic mouse livers. BMC Genomics 2009, 10:384-390.
29. Thatcher N.J., Caldwell J. Origins of hepatomegaly produced by dexamethasone (DEX), pregnenolone 16 alpha-carbonitrile (PCN) and phenobarbitone (PB) in female Sprague-Dawley rats. Biochem. Soc. Trans. 1994, 22:132S.
30. Toriyabe T., Nagata K., Takada T., Aratsu Y., Matsubara T., Yoshinari K., Yamazoe Y. Unveiling a new essential cis element for the transactivation of the CYP3A4 gene by xenobiotics. Mol. Pharmacol. 2009, 75:677-684.
31. Tuma D.J., Sorrell M.F., Barak A.J. Hepatic and serum lipid patterns during development of phenobarbital induced fatty livers in rats. Proc. Soc. Exp. Biol. Med. 1974, 146:953-956.
32. Ueda A., Hamadeh H.K., Webb H.K., Yamamoto Y., Sueyoshi T., Afshari C.A., Lehmann J.M., Negishi M. Diverse roles of the nuclear orphan receptor CAR in regulating hepatic genes in response to phenobarbital. Mol. Pharmacol. 2002, 61:1-6.
33. Waterham H.R., Koster J., Romeijn G.J., Hennekam R.C., Vreken P., Andersson H.C., FitzPatrick D.R., Kelley R.I., Wanders R.J. Mutations in the 3beta-hydroxysterol Delta24-reductase gene cause desmosterolosis, an autosomal recessive disorder of cholesterol biosynthesis. Am. J. Hum. Genet. 2001, 69:685-694.
34. Wu C., Miloslavskaya I., Demontis S., Maestro R., Galaktionov K. Regulation of cellular response to oncogenic and oxidative stress by Seladin-1. Nature 2004, 432:640-645.
35. Yamamoto Y., Moore R., Goldsworthy T.L., Negishi M., Maronpot R.R. The orphan nuclear receptor constitutive active/androstane receptor is essential for liver tumor promotion by phenobarbital in mice. Cancer Res. 2004, 64:7197-7200.
36. Yamazaki Y., Kakizaki S., Horiguchi N., Sohara N., Sato K., Takagi H., Mori M., Negishi M. The role of the nuclear receptor constitutive androstane receptor in the pathogenesis of non-alcoholic steatohepatitis. Gut 2007, 56:565-574.
37. Yoshinari K., Takagi S., Yoshimasa T., Sugatani J., Miwa M. Hepatic CYP3A expression is attenuated in obese mice fed a high-fat diet. Pharm. Res. 2006, 23:1188-1200.
38. Yoshinari K., Yoda N., Toriyabe T., Yamazoe Y. Constitutive androstane receptor transcriptionally activates human CYP1A1 and CYP1A2 genes through a common regulatory element in the 5'-flanking region. Biochem. Pharmacol. 2010, 79:261-269.